PMI Announces Plans to Scale Back Russian Operations

Apr.08.2022
PMI announces steps to suspend investments and reduce manufacturing operations in Russia, as well as plans to exit the market.

Following the announcement made on March 9, 2022, Philip Morris International Inc. (NYSE: PM) announced today the specific measures they have taken to temporarily halt investment plans and reduce their manufacturing business in Russia. PMI has taken the following actions:


Philip Morris International (PMI) has stopped offering some cigarette products in the market and reduced manufacturing activities accordingly. It has also halted marketing activities in the country and cancelled plans to launch all products, including its IQOS ILUMA flagship heated tobacco product in Russia by 2022. Plans to produce over 20 billion TEREA sticks (used for IQOS ILUMA) in Russia and invest $150 million have also been cancelled. Additionally, PMI's board of directors and senior executives are exploring options for an orderly exit from the Russian market due to the increasingly complex and rapidly changing regulatory and operational environment.


In the past four weeks, our main focus and all efforts have been to ensure the safety and security of our colleagues in Ukraine. We stand in solidarity with innocent men, women, and children who are suffering. "We employ over 3,200 people in Russia," said CEO Jacek Olczak. "We will continue to support them, including paying their salaries, and we will fulfill our legal obligations. Our priority will be to make decisions based on their safety and security.


As previously reported, Russia accounted for nearly 10% of PMI's total shipments in 2021, representing approximately 6% of the company's net income. PMI is set to release its Q1 2022 earnings announcement on April 21, 2022, which will include updated financial projections for the year.


Philip Morris International: Achieving a Smoke-Free Future


Philip Morris International (PMI) is a leading international tobacco company committed to achieving a smoke-free future and long-term development of its investment portfolio to include products beyond the tobacco and nicotine sectors. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including non-combustible heated, vapor, and orally consumed nicotine products, sold in markets outside the United States. Since 2008, PMI has invested over $9 billion to develop, scientifically validate, and commercialize smoke-free products for adult smokers who would otherwise continue smoking, with the goal of completely phasing out cigarette sales. This includes establishing world-class scientific evaluation capabilities, particularly in pre-clinical systematic toxicology, clinical and behavioural research, and post-market studies. The United States Food and Drug Administration (FDA) has authorized PMI's IQOS platform 1 device and consumables for marketing as a modified risk tobacco product (MRTP), concluding that the exposure modifications are appropriate for promoting public health. As of December 31, 2021, PMI's smoke-free products are available in 71 markets, and PMI estimates that approximately 15.3 million adult smokers have switched to IQOS and quit smoking globally. With a strong foundation in life sciences and expertise, PMI announced in February 2021 its ambitious expansion into the healthcare and medical sector, offering innovative products and solutions to meet unmet patient and consumer needs.


Link to original article:


The Philip Morris International (PMI) has announced the specific steps it will take to reduce its business operations in the Russian Federation, as well as its intent to withdraw from the market.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT Malaysia Launches Workforce Exercise to Improve Efficiency and Align With Future Business Direction
BAT Malaysia Launches Workforce Exercise to Improve Efficiency and Align With Future Business Direction
British American Tobacco Malaysia has announced a workforce optimisation exercise aimed at streamlining operations ahead of a major shift in its distribution strategy.
Apr.01 by 2FIRSTS.ai
European Commission Publishes Tobacco Control Framework Evaluation, Says Smoking and Tobacco-Related Deaths Have Declined
European Commission Publishes Tobacco Control Framework Evaluation, Says Smoking and Tobacco-Related Deaths Have Declined
The European Commission has published its evaluation of the EU tobacco control framework, assessing the effectiveness, efficiency and relevance of the Tobacco Products Directive and Tobacco Advertising Directive in protecting public health and ensuring the smooth functioning of the internal market.
Apr.03 by 2FIRSTS.ai
UK Opens Applications for Vaping Products Duty and Duty Stamps Scheme From April 1
UK Opens Applications for Vaping Products Duty and Duty Stamps Scheme From April 1
HM Revenue and Customs announced that from April 1, 2026, UK vaping product manufacturers, importers and warehousekeepers can apply for approval under Vaping Products Duty (VPD) and the Vaping Duty Stamps Scheme (VDS). Under new GOV.UK guidance, Vaping Products Duty will take effect on October 1, 2026 and will apply to all vaping liquids, whether they contain nicotine or not.
Apr.02 by 2FIRSTS.ai
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
The U.S. Food and Drug Administration issued guidance on May 8, 2026, titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” The document describes FDA enforcement policies for certain electronic nicotine delivery system products and nicotine pouch products marketed without premarket authorization.
May.09 by 2FIRSTS.ai
KT&G Moves Ahead With Oral Nicotine Product Development and Pilot Line Preparation
KT&G Moves Ahead With Oral Nicotine Product Development and Pilot Line Preparation
According to a Korean media report, KT&G is developing a smokeless nicotine product that delivers nicotine through oral absorption and is preparing a pilot production line for research and development.
Apr.08 by 2FIRSTS.ai
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13